Ultragenyx Pharmaceutical Inc(RARE)11月5日公布2024年第三季度财报数据后盘后大跌5.46%,引发市场的广泛关注。财报显示,公司第三季度调整后每股亏损1.40美元,略好于华尔街分析师预期每股亏损1.45美元。
公司本季度营收达到1.395亿美元,同比增长42.3%,超出分析师预期1.358亿美元。尽管营收实现强劲增长,但公司一季度净亏损进一步扩大至1.335亿美元。
分析师认为,虽然Ultragenyx营收持续保持较快增长,但公司获利能力仍面临一定压力。今年迄今为止,Ultragenyx股价只上涨了6.8%,落后于同行和大盘。投资者对公司前景产生一定疑虑,导致财报公布后公司股价出现大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.